Physician profile
Rupam Sharan
NPI 1972611309
$1,474.27
in general payments reported to CMS, 2019-2025
17 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.43 · 2020: $15.49 · 2021: $101 · 2022: $280 · 2023: $356 · 2024: $369 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.30 | 2022-2025 | Skyrizi, Rinvoq |
| Abbott Laboratories | $101.18 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $98.87 | 2022-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $73.74 | 2024-2025 | Eohilia |
| Pfizer INC. | $68.98 | 2025 | |
| Merck Sharp & Dohme LLC | $58.84 | 2022-2023 | Dificid |
| Madrigal Pharmaceuticals | $53.07 | 2025 | Rezdiffra |
| Beone Medicines USA, INC. | $46.29 | 2025 | Tevimbra |
| Pharmacosmos Therapeutics INC. | $37.54 | 2022 | |
| Ironwood Pharmaceuticals, INC | $36.93 | 2023 | Linzess |
| Janssen Biotech, INC. | $33.76 | 2023 | Stelara |
| Celgene Corporation | $23.90 | 2024 | Zeposia |
| Genzyme Corporation | $20.46 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.31 | 2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $19.18 | 2023 | Clenpiq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $15.49 | 2020 | |
| Vivus LLC | $10.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupam Sharan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.